Cefazolin IV + Linezolid IV + Vancomycin (IV)
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bacteremia
Conditions
Bacteremia, Gram-Positive Bacterial Infections
Trial Timeline
Sep 1, 2005 → Sep 1, 2006
NCT ID
NCT00108433About Cefazolin IV + Linezolid IV + Vancomycin (IV)
Cefazolin IV + Linezolid IV + Vancomycin (IV) is a phase 3 stage product being developed by Pfizer for Bacteremia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00108433. Target conditions include Bacteremia, Gram-Positive Bacterial Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00108433 | Phase 3 | Terminated |
Competing Products
9 competing products in Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin + Comparator | Merck | Approved | 85 |
| Daptomycin for Injection | Merck | Phase 2 | 52 |
| Vancomycin + Daptomycin | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 77 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| ceftobiprole medocaril | Basilea Pharmaceutica | Phase 2 | 47 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| AP-SA02 | Armata Pharmaceuticals | Phase 1/2 | 33 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |